Periodontal Disease Therapeutics MarketSize and Trends

Periodontitis is a chronic bacterial infection caused by microbial plaque often known as gum disease that is colonized on tooth surface and below the gingival margin. It involves progressive loss of the alveolar bone, which is a thickened ridge of bone that contains tooth socket over the bones that holds teeth. According to National Institutes of Health 2017, around 20-15% of global population is estimated to suffer from severe periodontitis in comparison to 5-10% in 2004, which is propelling demand for its diagnosis and treatment worldwide in the medical industry.

In periodontitis, gums are pulled away from teeth and form spaces (pockets), which are prone to get infected. If such infection is untreated, it can lead to increase periodontal pocket length and bleeding on probe, in turn leading to the alveolar bone loss and teeth loss. In order to complement a non-surgical therapy in periodontitis multiple antimicrobial options are available, such as metronidazole, chlorhexidine, minocycline, doxycycline, tetracycline, which can be locally delivered to mucosa. These drugs are used to inhibit periodontopathogenic microorganism as well as modulate the inflammatory response of tissues.

Periodontal Disease Therapeutics Market Drivers

Oral care and dental hygiene are one of the major concerns worldwide. High prevalence of periodontal disease is propelling demand for oral treatment. Periodontal disease is a result of various risk factors, such as aging, smoking, poor oral hygiene, heredity, stress, and other medical conditions.

Periodontal disease are majorly observed in adults. According to the Centre for Disease Control and Prevention (CDC), in 2018, the prevalence of periodontitis has been estimated to be over 50% in U.S. adults aged 30 years and older i.e. 64.7 million Americans. Among those adults, 8.7% showed mild disease, 30% demonstrated moderate disease, 8.5% had severe chronic periodontitis. Disease prevalence increases with age, with 70% adults, who are 65 years and above, suffering from periodontitis. There are many environmental risk factors that are associated with inflammatory responses, which include smoking, diabetes mellitus, and poor health habits driving the chronic inflammatory response in periodontitis, and are beneficial for the periodontitis disease therapeutic market.

Also, advancements in treatment by using novel drugs is expected to fuel the periodontal disease therapeutics market growth. For instance, in January 2017, ST266 by Noveome Biotherapeutics, Inc., is an expected candidate for disease treatment, which is currently in phase I clinical trials. ST266, is used to treat patients with moderate to severe periodontitis. It provide essential tools at critical stages of the healing process to restore homeostasis within the periodontal microenvironment.

Local antibiotics for the treatment of periodontal disease to present more growth opportunities in the periodontal disease therapeutics market. Increasing preference for controlled local drug delivery approaches over systemic drug delivery due to better therapeutic outcomes by achieving factors such as site specific delivery, low dose requirement, reduces side effects favors the growth of local antibiotics. Furthermore, it provide safe and effective mode of treatment and is expected to lead the market in the next few years due to various advantages. Systemic antibiotics is expected to hold dominance in global market due to factors such as product affordability, availability, and high market penetration. Growing number of preventive care for dental and gum problems and poor reimbursement policies in many economies are hindering the growth of periodontal disease therapeutic market.